Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s plans to capture share and become the market leader in neurovascular.

Carsten Schroeder, president and CEO of Terumo Neuro, discusses the company’s rebranding, plans for growth and becoming the market leader in neuroendovascular technologies in an interview with SmartTRAK. Listen to the video below to find out more, including how Terumo plans to innovate and take share via new disease states and markets in addition to its core neurovascular markets (ischemic, hemorrhagic and access).

Click on the video below to watch the interview (32:05 min). A link to download the complete transcript of the interview is available here. For more details, interview topics by timecode are provided below.

In 2024, SmartTRAK continued to empower you to Be The Expert in the MedTech industry. As your trusted resource for up-to-date industry insights, we delivered real-time market data, analysis and actionable insights across the orthopedics, wound care, regenerative medicine and neurotherapy markets. Here are SmartTRAK's Top Blog Posts from 2024, offering valuable perspectives from our expert analysts.

1. Skin Substitute Market Rocked by DOJ Investigations
   SmartTRAK believes the billions of dollars of Medicare abuse already uncovered is the tip of the iceberg in services billed to Medicare via the Physician Fee Schedule.
   
   
2. Medtronic: Making Waves At NANS 2024
   Medtronic executives discuss how the company is making waves in interventional pain, minimally invasive spine and deep brain stimulation in an interview with SmartTRAK at NANS 2024.
   
   
3. Spine Market Movers to Watch in 2024
   SmartTRAK highlights companies to watch as they continue their double-digit growth train with multiple catalysts for expansion in 2024.
   
   
   
   

Q’Apel Medical CEO Jodie Fam discusses the company, strategies for growth and Q’Apel’s approach to innovation in an interview with SmartTRAK at SVIN 2024. 

Q’Apel Medical CEO Jodie Fam discusses the company, its technologies, strategies for growth and Q’Apel’s approach to innovation in an interview with SmartTRAK at the Society of Vascular and Interventional Neurology (SVIN) held November 22-24, 2024 in San Diego, California. 

To find out more, click on the video below to listen to the interview (22:08 min). Click the button below to download a complete transcript of the interview.

Amaza Reitmeier, Medtronic’s VP and GM of Brain Modulation, discusses the company’s recent FDA approvals for asleep DBS and expanded MRI labeling, and provides an update on adaptive DBS in an interview with SmartTRAK. 

In an interview with SmartTRAK, Medtronic’s Amaza Reitmeier, vice president and general manager of Brain Modulation, discusses the company’s recent news in deep brain stimulation (DBS), including FDA approval for asleep DBS and MRI expanded labeling that allows patients to undergo additional scan time. She also provides an update on adaptive DBS (aDBS) and the ADAPT-PD trial, which is expected to support the global regulatory submissions to commercialize aDBS in patients with PD.  Medtronic recently filed for US FDA approval of aDBS.

Click on the following video to listen to the interview (14:32 minutes). A link to download a complete transcript of the interview is also provided below.
 

Interview Transcript

SmartTRAK: Hey everybody. Anne Staylor here with SmartTRAK. Today I get to talk to Amaza Reitmeier, the vice president and general manager of Brain Modulation at Medtronic. Hey Amaza, thanks for talking with me.

Amaza Reitmeier: Hi, Anne. Great to see you.

I know that you have some big news around DBS. You guys are advancing pretty quickly. The latest news involves FDA approval for asleep vs awake DBS, MRI expanded labeling, and then maybe you could give me an update on some other aspects of the adaptive DBS. So let's get started.

AR: Fantastic.

What is the significance? Talk a little bit about the FDA approval for asleep vs awake DBS, and why is that important? A lot of people are doing that. Just talk a little bit about the significance of that and what it means for Medtronic.

AR: Thank you, Anne. Well, first and foremost, you know from our prior conversations that we're very focused on the patient and making sure that patients have the best options available to them. While you're right that asleep DBS has been being done for years, it's actually been contraindicated in our labeling. The original labeling for DBS, which was established decades ago, required test stimulation to confirm that the therapy was working. But we also know that ...

Click the button below to download and read the full transcript of the SmartTRAK perspective article "Transforming DBS Therapy - An Interview with Amaza Reitmeier" conducted by Anne Staylor, SmartTRAK's Executive Editor and VP & GM of Neuro Therapies.

SmartTRAK's Anne Staylor, VP & GM Neuro Therapies, will be attending ESMINT 2024

SmartTRAK is excited to attend the ESMINT Congress 2024, which will be held at the Pharo Congress Center in Marseille, France, September 4-6. Anne Staylor, SmartTRAK VP & GM Neuro Therapies, will be there to cover the latest Neurovascular news and developments. In this Market Snapshot video update, Anne provides the latest research and technologies impacting the market for neuro intervention, including trends to look for at the meeting.

If you'd like to meet with Anne at ESMINT, or see more of SmartTRAK's neuro coverage, just click the button below to visit SmartTRAK Neurovascular Central.

Ariel Sutton, EVP and GM of Imperative Care’s Stroke business, discusses the Imperative Trial, the company’s Zoom Insert Catheters and more in an interview with SmartTRAK at SNIS 2024. 

Imperative Care’s Ariel Sutton, executive vice president and general manager of the company’s Stroke business, discusses results from the Imperative Trial, what it means for the acute ischemic stroke (AIS) market and the company’s newest innovations in an interview with SmartTRAK at the Society of NeuroInterventional Surgeons (SNIS) 21^st Annual meeting in Colorado Springs, CO held July 22 to 26, 2024.

To find out more, listen to the following video (15:54 minutes). A link to download the complete transcript of the interview is also provided below. 

Interview Transcript (scroll down to download the complete transcript)

SmartTRAK: Anne Staylor here with SmartTRAK. Today I am speaking with Ariel Sutton, EVP and GM of Imperative Care Stroke Business, live from the Society of NeuroInterventional Surgeons annual meeting in Colorado Springs. Ariel, thank you for talking with me today.

Ariel Sutton: Thank you for having me.

Let's start by having you talk about Imperative Care's presence at SNIS. What's important for us to know?

AS: We’re really excited to share the results of the Imperative Trial at SNIS this year. This is a 260-patient prospective trial across 26 centers in the US, evaluating the clinical benefits of the Zoom Stroke Solution, including aspiration with our Zoom 88 catheters. The results from the trial showed high reperfusion rates of 82.2% TICI 2B+, which is similar to previous studies that were submitted to the FDA for 510(k) clearance for reperfusion indication. There are a few metrics that we think are important to highlight from the trial. First is ...  

Click the button below to download and read the full transcript of the interview "SNIS 2024: An Interview with Imperative Care's Ariel Sutton" , conducted by Anne Staylor, SmartTRAK's Executive Editor and VP & GM of Neuro Therapies.